Vita 34 International : records increasing number of uses of umbilical cord blood

12.12.2018 / 13:56
The issuer is solely responsible for the content of this announcement.

Vita 34 records increasing number of uses of umbilical cord blood

- Already 5th application from stock in the current year

- Noticeably increasing number of use cases

- Highest number of applications within one year

Leipzig, 12 December 2018 - Vita 34 AG (ISIN: DE000A0BL849, WKN: A0BL84), the second largest cord blood bank in Europe, can record the 35th use of umbilical cord blood from its stock. This means that five applications with umbilical cord blood from the Vita 34 portfolio have already been successfully carried out in the current year. Further blood for application has already been requested.

In the increasing number of applications, a trend manifests itself, which is mainly due to the pioneering work of Prof. Joanne Kurtzberg of Duke University (NC, USA). In a recently published study, she was able to show that in children with cerebral palsies or with autism, the use of umbilical cord blood in a dose-dependent manner can bring significant improvements in the clinical picture. In the most recent application, the transfusion was administered without complications to an eight-month-old boy in a German clinic.

'Cord blood applications are still considered to be experimental today,' explains Dr. Wolfgang Knirsch, CEO of Vita 34 AG. 'However, the consistently expanding scope of application will undoubtedly have a positive effect on the perception of our range of services in the medium and long term and lead to an increased willingness of expectant parents to opt for umbilical cord blood or umbilical cord tissue storage.'

In the coming years, the company expects increasing dynamics of storage numbers. The development program of Vita 34 for the isolation of immune cells from umbilical cord blood will increasingly expand the range of services and thus open up further relevant applications in the field of personalized cell medicine. New product offerings, such as the storage of endogenous adipose tissue and peripheral blood, will in the future also enable adults to store their own cells and benefit from further medical progress.

Contact:
Ingo Middelmenne
Investor Relations
Vita 34 AG

Phone: [phone] - 0
Mobile: [phone]
Email: [e-mail]

Company Profile

Vita 34 was founded in Leipzig in 1997 as the first private cord blood bank in Europe and, as a complete provider of cryo-preservation services, offers collection, logistics, preparation, and storage of stem cells from umbilical cord blood and tissue. Stem cells are a valuable base material for medical cell therapy and are kept alive at temperatures of minus 200 degrees Celsius in order to be available for use in a treatment if needed. More than 200,000 customers from more than 20 countries have already provided for their family's health with a stem cell depot at Vita 34.

12.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de